Switching IVIG to weekly SCIG for CIDP treatment
Part of Blood & lymphatic, Brain & nervous system, Hormones & metabolism, Immune system & allergy clinical trials.
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old and have a confirmed CIDP diagnosis
- You are already taking IVIG for CIDP (not for another condition)
- Your weekly IVIG dose can be safely converted to a weekly SCIG dose in the study’s target range
- Your liver function is not significantly elevated (no more than 3× the normal limit)
- Your kidneys work well enough (creatinine clearance 50 mL/min or higher)
- You do not have certain other conditions such as active cancer, diabetes, or immune-related disorders
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.
This Phase 2 study compares a blood-cleansing treatment (immunoadsorption) with standard immune-boosting treatment (intravenous immunoglobulins) for chronic inflammatory demyelinating polyneuropathy (CIDP). It may help people whose steroid treatment did not work well, or who cannot take steroids.
This trial tests whether a blood-filtering treatment called immunoadsorption can help people with CIDP. It is for adults who are already receiving or starting IVIg or MP therapy.
This study looks at people with CIDP who are stable on IVIg treatment to see if we can predict when they might get worse if their treatment is adjusted. It aims to make treatment management easier and more personalized.
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
This study looks at how well efgartigimod works in everyday use for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to understand the real-world benefits of this treatment.
Hear when a new CIDP trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.